PMID- 11698073
OWN - NLM
STAT- MEDLINE
DCOM- 20020103
LR  - 20201208
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 430
IP  - 1
DP  - 2001 Oct 26
TI  - Regulation of immunoglobulin E-mediated secretion by protein phosphatases in 
      human basophils and mast cells of skin and lung.
PG  - 135-41
AB  - A wide range of serine/threonine protein phosphatase (PP) inhibitors were studied 
      for effects on the immunoglobulin E (IgE)-mediated release of histamine from 
      human lung mast cells, human skin mast cells and basophils. Okadaic acid (OA) 
      inhibited the release of histamine from all three cell types in a 
      concentration-dependent manner. Two structural analogues of okadaic acid, okadaol 
      and okadaone, known to be less active than the parent molecule as inhibitors of 
      PP, were less active than okadaic acid as inhibitors of histamine release in 
      these three cell types. A number of PP inhibitors, showing differences in 
      selectivity for PP1 and PP2A, were also evaluated. Calyculin, which is roughly 
      equipotent as a PP1 and PP2A inhibitor, attenuated the release of histamine from 
      all three cell types. Similarly, tautomycin (TAU), which shows greater 
      selectivity for PP1 over PP2A, was also effective at inhibiting histamine release 
      in all three cell types. In contrast, fostriecin, which is very much more potent 
      as an inhibitor of PP2A over PP1, was ineffective as an inhibitor in all three 
      cell types. These data indicate that the regulation of mediator release by PPs is 
      similar in lung mast cells, skin mast cells and basophils. Moreover, the data 
      suggest that PP1 is important in the control of cellular activity.
FAU - Bastan, R
AU  - Bastan R
AD  - Section of Molecular Pharmacology and Pharmacogenetics, University of Sheffield, 
      The Royal Hallamshire Hospital (Floor L), Glossop Road, S10 2JF, Sheffield, UK.
FAU - Peirce, M J
AU  - Peirce MJ
FAU - Peachell, P T
AU  - Peachell PT
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Alkenes)
RN  - 0 (Antifungal Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Marine Toxins)
RN  - 0 (Oxazoles)
RN  - 0 (Polyenes)
RN  - 0 (Pyrans)
RN  - 0 (Pyrones)
RN  - 0 (Spiro Compounds)
RN  - 109946-35-2 (tautomycin)
RN  - 1W21G5Q4N2 (Okadaic Acid)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 7D07U14TK3 (calyculin A)
RN  - EC 3.1.3.16 (Phosphoprotein Phosphatases)
RN  - ZO1648L551 (fostriecin)
SB  - IM
MH  - Alkenes/pharmacology
MH  - Antifungal Agents/pharmacology
MH  - Basophils/drug effects/immunology
MH  - Enzyme Inhibitors/pharmacology
MH  - Histamine Release/drug effects
MH  - Humans
MH  - Immunoglobulin E/*metabolism
MH  - Lung/*drug effects
MH  - Marine Toxins
MH  - Mast Cells/drug effects/immunology
MH  - Okadaic Acid/pharmacology
MH  - Oxazoles/pharmacology
MH  - Phosphoprotein Phosphatases/antagonists & inhibitors/*physiology
MH  - Polyenes
MH  - *Pyrans
MH  - Pyrones
MH  - Skin/*drug effects
MH  - *Spiro Compounds
EDAT- 2001/11/08 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/08 10:00
PHST- 2001/11/08 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/08 10:00 [entrez]
AID - S0014299901013668 [pii]
AID - 10.1016/s0014-2999(01)01366-8 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2001 Oct 26;430(1):135-41. doi: 10.1016/s0014-2999(01)01366-8.